iData Insights

Partial Seizure - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 30, 2016 12:10 IST

Partial Seizure - Pipeline Review, H2 2015 Summary Global Markets Direct s, Partial Seizure - Pipeline Review, H2 2015, provides an overview of the Partial Seizures therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Partial Seizure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Partial Seizure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 6

Global Markets Direct Report Coverage 6

Partial Seizure Overview 7

Therapeutics Development 8

Pipeline Products for Partial Seizure - Overview 8

Partial Seizure - Therapeutics under Development by Companies 9

Partial Seizure - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Partial Seizure - Products under Development by Companies 13

Partial Seizure - Companies Involved in Therapeutics Development 14

Advicenne Pharma 14

Catalyst Pharmaceutical Partners, Inc. 15

Eisai Co., Ltd. 16

Marinus Pharmaceuticals, Inc. 17

Novartis AG 18

SciFluor Life Sciences, LLC 19

SK Biopharmaceuticals Co., Ltd. 20

UCB S.A. 21

Partial Seizure - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 30

brivaracetam - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

clobazam - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

CPP-115 - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

everolimus - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ganaxolone - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

lacosamide - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

levetiracetam - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

MB-003 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

perampanel - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

selurampanel - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

SF-0034 - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

YKP-3089 - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Partial Seizure - Recent Pipeline Updates 59

Partial Seizure - Dormant Projects 82

Partial Seizure - Discontinued Products 83

Partial Seizure - Product Development Milestones 84

Featured News & Press Releases 84

Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan 84

Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting 85

Jan 05, 2015: Phase III Trial of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint 87

Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy 87

Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting 89

Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment 89

Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 90

Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 91

Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society 92

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects